FDA Commissioner Marty Makary is leaving after Trump approved his removal plan, amid policy clashes over vaping, abortion pills, and broader unrest.
A high-profile shakeup in the Trump administration has hit the FDA: Commissioner Marty Makary is set to leave. after President Donald Trump signed off on a plan to remove him earlier in May. according to reports citing people familiar with the matter.. The decision comes just months before the 2026 midterm elections and signals how quickly leadership and policy lines are shifting inside major health agencies.
Makary’s departure reflects mounting pressure from within the White House and from Health and Human Services officials, sources say.. He was confirmed as FDA commissioner in March 2025. but during his time in the role. policy disputes and internal clashes at the agency reportedly intensified—leaving allies and staff bracing for the possibility that his position would become untenable.
One of the most significant flashpoints reportedly centered on flavored electronic cigarettes.. Sources familiar with the situation say Makary resisted efforts to approve fruit-flavored vaping products. citing concerns about how such flavors may appeal to children.. The dispute escalated to the point that Trump directly confronted Makary over vape policy decisions, according to the reports.
Earlier in May. the FDA reportedly reversed course and moved toward approving flavored e-cigarette products. a shift that reignited speculation that Makary’s ability to lead was rapidly weakening.. For observers. the timing of the agency’s change and the president’s subsequent confirmation of the removal plan fed a clear narrative: when policy outcomes diverged from internal expectations. the commissioner’s role became the pressure point.
Trump later confirmed Makary’s exit in a post on Truth Social.. In that announcement, Trump named Kyle Diamantas, who currently oversees the FDA’s food division, to serve as acting commissioner.. The leadership change is also expected to deepen a broader challenge across the Department of Health and Human Services. which sources indicate is already operating without permanent leaders at both the Centers for Disease Control and Prevention and the surgeon general’s office.
Adding another layer to the reaction. reports say some of Makary’s allies were caught off guard after he had privately suggested he believed Trump still supported him.. That sense of misalignment between internal reassurance and external action appears to have contributed to the surprise surrounding his planned removal.
Shortly after the news broke, Secretary Robert F.. Kennedy Jr.. publicly praised Makary on X.. Kennedy described Makary as having taken on entrenched interests. challenged the status quo. and “never lost sight of the American people” while pushing critical reforms connected to the stated goal of “Make America Healthy Again.” Kennedy also said he was grateful for Makary’s courage and friendship and wished him well in his next chapter. while indicating that a search for a new commissioner was already underway with urgency.
Makary had been scheduled to testify before the Senate Appropriations Committee about the FDA’s proposed budget just one day after the departure news came out, raising questions about how the transition may affect upcoming oversight and planning at the agency.
Pressure also came from anti-abortion groups dissatisfied with the FDA’s posture on abortion medication.. The reports say Susan B.. Anthony Pro-Life America President Marjorie Dannenfelser met with White House officials to push for tighter restrictions on mifepristone. an abortion pill that can currently be prescribed through telehealth and mailed nationwide under FDA regulations.. Dannenfelser said Makary should be fired immediately. describing the administration’s position as “indifference” that she said is unacceptable to pro-life voters who expect action.
Beyond vaping and abortion-related policy. Makary’s tenure was reportedly shaped by competing pressure from different political factions within Trump’s coalition.. Sources say some pharmaceutical companies criticized his approach to drug approvals. while vaccine skeptics connected to the Make America Healthy Again movement argued he had not pushed hard enough in challenging COVID-19 vaccines.
At the same time, other supporters pointed to Makary’s efforts targeting artificial food dyes and ultra-processed foods.. That mix of praise and backlash underscores a recurring theme in the FDA’s leadership politics: the commissioner’s decisions can quickly become a proxy for larger fights over public health priorities. regulatory philosophy. and which constituencies the administration should prioritize.
For the White House. the decision to clear space at the top of the FDA could be seen as an attempt to reset policy momentum ahead of a politically sensitive midterm period.. For the agency itself. however. the change also means more turnover at a moment when multiple major health institutions remain without permanent leadership—raising the stakes for who ultimately sets the tone on enforcement. approvals. and future regulatory direction.
Marty Makary FDA commissioner Trump administration shakeup flavored vaping products mifepristone abortion pill Kyle Diamantas acting commissioner Truth Social announcement Robert F. Kennedy Jr.